Marginal zone B cells acquire dendritic cell functions by trogocytosis
Marginal zone (MZ) B cells produce broad-spectrum antibodies that protect against infection early in life. In some instances, antibody production requires MZ B cells to display pathogen antigens bound to major histocompatibility complex class II (MHC II) molecules to T cells. We describe the trogocytic acquisition of these molecules from conventional dendritic cells (cDCs). Complement component 3 (C3) binds to murine and human MHC II on cDCs. MZ B cells recognize C3 with complement receptor 2 (CR2) and trogocytose the MHC II-C3 complexes, which become exposed on their cell surface. The ubiquitin ligase MARCH1 limits the number of MHC II-C3 complexes displayed on cDCs to prevent their elimination through excessive trogocytosis. Capture of C3 by MHC II thus enables the transfer of cDC-like properties to MZ B cells.
| Errataetall: |
CommentIn: Trends Immunol. 2022 May;43(5):340-342. - PMID 35379581 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:375 |
|---|---|
| Enthalten in: |
Science (New York, N.Y.) - 375(2022), 6581 vom: 11. Feb., Seite eabf7470 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schriek, Patrick [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.02.2022 Date Revised 12.05.2022 published: Print-Electronic CommentIn: Trends Immunol. 2022 May;43(5):340-342. - PMID 35379581 Citation Status MEDLINE |
|---|
| doi: |
10.1126/science.abf7470 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336755279 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336755279 | ||
| 003 | DE-627 | ||
| 005 | 20231225232849.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/science.abf7470 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1122.xml |
| 035 | |a (DE-627)NLM336755279 | ||
| 035 | |a (NLM)35143312 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schriek, Patrick |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Marginal zone B cells acquire dendritic cell functions by trogocytosis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.02.2022 | ||
| 500 | |a Date Revised 12.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Trends Immunol. 2022 May;43(5):340-342. - PMID 35379581 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Marginal zone (MZ) B cells produce broad-spectrum antibodies that protect against infection early in life. In some instances, antibody production requires MZ B cells to display pathogen antigens bound to major histocompatibility complex class II (MHC II) molecules to T cells. We describe the trogocytic acquisition of these molecules from conventional dendritic cells (cDCs). Complement component 3 (C3) binds to murine and human MHC II on cDCs. MZ B cells recognize C3 with complement receptor 2 (CR2) and trogocytose the MHC II-C3 complexes, which become exposed on their cell surface. The ubiquitin ligase MARCH1 limits the number of MHC II-C3 complexes displayed on cDCs to prevent their elimination through excessive trogocytosis. Capture of C3 by MHC II thus enables the transfer of cDC-like properties to MZ B cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a C3 protein, human |2 NLM | |
| 650 | 7 | |a Complement C3 |2 NLM | |
| 650 | 7 | |a HLA-D Antigens |2 NLM | |
| 650 | 7 | |a Histocompatibility Antigens Class II |2 NLM | |
| 650 | 7 | |a Receptors, Complement 3d |2 NLM | |
| 650 | 7 | |a MARCH1 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.3.2.27 |2 NLM | |
| 650 | 7 | |a MARCHF1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.3.2.27 |2 NLM | |
| 650 | 7 | |a Ubiquitin-Protein Ligases |2 NLM | |
| 650 | 7 | |a EC 2.3.2.27 |2 NLM | |
| 700 | 1 | |a Ching, Alan C |e verfasserin |4 aut | |
| 700 | 1 | |a Moily, Nagaraj S |e verfasserin |4 aut | |
| 700 | 1 | |a Moffat, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Beattie, Lynette |e verfasserin |4 aut | |
| 700 | 1 | |a Steiner, Thiago M |e verfasserin |4 aut | |
| 700 | 1 | |a Hosking, Laine M |e verfasserin |4 aut | |
| 700 | 1 | |a Thurman, Joshua M |e verfasserin |4 aut | |
| 700 | 1 | |a Holers, V Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Ishido, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Lahoud, Mireille H |e verfasserin |4 aut | |
| 700 | 1 | |a Caminschi, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Heath, William R |e verfasserin |4 aut | |
| 700 | 1 | |a Mintern, Justine D |e verfasserin |4 aut | |
| 700 | 1 | |a Villadangos, Jose A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science (New York, N.Y.) |d 1880 |g 375(2022), 6581 vom: 11. Feb., Seite eabf7470 |w (DE-627)NLM000023450 |x 1095-9203 |7 nnns |
| 773 | 1 | 8 | |g volume:375 |g year:2022 |g number:6581 |g day:11 |g month:02 |g pages:eabf7470 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/science.abf7470 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 375 |j 2022 |e 6581 |b 11 |c 02 |h eabf7470 | ||